Dossier - 10/02/2014 Multiresistant pathogens – a self-inflicted threat? Most bacterial infections have lost their capacity to cause terror thanks to antibiotics. However, the increase in antibiotic resistances is making the fight against bacterial pathogens rather difficult, and the widespread overuse and inappropriate use of antibiotics continues to fuel the increase in antibiotic-resistant bacteria. Strict surveillance strategies and hygiene rules have been in place for some years with the aim of ensuring the…https://www.gesundheitsindustrie-bw.de/en/article/dossier/multiresistant-pathogens-a-self-inflicted-threat
Article - 18/02/2009 Dormant stem cells can be awakened with interferon alpha With a number of new papers published in renowned scientific journals Prof. Dr. Andreas Trumpp has been able to further cement his outstanding reputation as one of the world leaders in stem cell research. Trumpp who has been professor and head of the Department of Cell Biology at the German Cancer Research Centre DKFZ since summer 2008 also became head of the newly founded Heidelberg Institute for Stem Cell Technology and Experimental Medicine…https://www.gesundheitsindustrie-bw.de/en/article/news/dormant-stem-cells-can-be-awakened-with-interferon-alpha
Article - 12/10/2009 Gudula Schmidt: E. coli and the rigid cytoskeleton Many bacterial toxins destroy the shape and function of their host cells – some of them degrade the cytoskeleton, others have a tendency to inhibit the elasticity of the cytoskeleton. Prof. Dr. Gudula Schmidt and her team at the University of Freiburg are investigating the effect of the substance CNF-1 and have already discovered the mechanism that is initiated by this toxin.https://www.gesundheitsindustrie-bw.de/en/article/news/gudula-schmidt-e-coli-and-the-rigid-cytoskeleton
Article - 15/10/2012 ERC Starting Grants 2012: Baden-Württemberg achieves above-average success On September 10th 2012, the European Research Council (ERC) announced the results of the fifth funding round of its Starting Grants. Baden-Württemberg was awarded 13 grants, and is the state with the largest number of a total of 34 grants awarded to German life sciences researchers. Baden-Württemberg life sciences researchers will be receiving Starting Grants worth around 20 million euros.https://www.gesundheitsindustrie-bw.de/en/article/news/erc-starting-grants-2012-baden-wuerttemberg-achieves-above-average-success
Press release - 01/10/2008 Karin Scharffetter-Kochanek: research that gets under the skin Prof. Karin Scharffetter-Kochanek has recently become a member of the renowned Leopoldina Academy of Sciences. In her research the skin has become a model system that serves as the basis for a trans-organ systemic approach looking at the underlying mechanisms and the complex interactions with other organs.https://www.gesundheitsindustrie-bw.de/en/article/press-release/karin-scharffetter-kochanek-research-that-gets-under-the-skin
Article - 28/11/2011 Oliver Schilling – the function of proteases in molecular processes The biologist Dr. Oliver Schilling from the University of Freiburg has co-developed methods that improve our understanding of the function of proteases in molecular processes. His research group is currently investigating cellular processes that are regulated by these proteolytic enzymes and looking into issues such as the key role they play in tumour development.https://www.gesundheitsindustrie-bw.de/en/article/news/oliver-schilling-the-function-of-proteases-in-molecular-processes
Press release - 27/08/2018 Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets Affimed will receive $96 million upfront and committed funding and is eligible for up to an additional $5.0 billion including milestone payments, and royalties on sales.https://www.gesundheitsindustrie-bw.de/en/article/press-release/affimed-announces-collaboration-with-genentech-to-develop-novel-nk-cell-engager-based-immunotherapeutics-for-multiple-cancer-tar
Press release - 04/10/2017 Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies Tuebingen, Germany and Houston, Texas, October 4, 2017 – Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financing, raising $58 million.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-receives-58-million-in-financing-to-develop-t-cell-receptor-based-immunotherapies
Article - 16/07/2012 Laupheim to become an international forum for biomanufacturing The 2nd Laupheimer Zelltage conference organized by Rentschler Biotechnologie GmbH in Laupheim on 11th and 12th June 2012 focused on “Bioprocess light”. Twelve experts from applied research institutions and biotech companies from Germany and abroad provided the 200 or so guests with information on how modern bioproduction methods can be made simpler, more robust, cheaper, more reliable and hence more competitive.https://www.gesundheitsindustrie-bw.de/en/article/news/laupheim-to-become-an-international-forum-for-biomanufacturing
Article - 20/12/2010 Invisible danger with long-term consequences According to official figures mycotoxins which are toxic secondary metabolites produced by moulds are found in around of 20 per cent of the European crop harvest. Even the smallest concentrations of mycotoxins can have devastating toxic effects causing cancer or posing a risk to fertility and development. Alexandra Heussner from the University of Konstanz is investigating ochratoxins whose chronic effect represents a huge danger to human health.https://www.gesundheitsindustrie-bw.de/en/article/news/invisible-danger-with-long-term-consequences
Article - 09/02/2008 A better alternative from the perspective of embryo protection Karin Bundschuh of BIOPRO Baden-Württemberg asked Dr. Jens Clausen how these developments should be viewed from an ethical perspective. The bioethicist spent many years studying the status of embryos the ethics of cloning and stem cell research.https://www.gesundheitsindustrie-bw.de/en/article/news/a-better-alternative-from-the-perspective-of-embryo-protection
Article - 04/04/2011 FreiBiotics GmbH – new drugs against resistant bacteria Bacteria adapt quickly to their environment and also to antibiotics. Many of the antibiotics used to treat bacterial infections have become ineffective as a great many bacteria have become resistant to them. Freiburg-based FreiBiotics GmbH is looking for completely new classes of antimicrobial substances. A screening method that has been developed over the last few years based on biosensors makes the identification of new substance classes more…https://www.gesundheitsindustrie-bw.de/en/article/news/freibiotics-gmbh-new-drugs-against-resistant-bacteria
Article - 13/03/2010 Assembling life from building blocks? As part of its “Bioethics Forum”, the German Ethics Council recently held a meeting in Berlin to inform the public about the fundamentals of synthetic biology and potential ethical problems and consequences in terms of our ideas about life and mankind in general arising from the progress made in this new field of research. https://www.gesundheitsindustrie-bw.de/en/article/news/assembling-life-from-building-blocks
Article - 11/06/2019 New pathogens in beef and cow's milk contributing to the risk of cancer A team of researchers led by Nobel laureate Prof. Dr. med. Dr. h.c. mult. Harald zur Hausen has discovered a new type of infectious agent in dairy and meat products produced from European cattle that increases the risk for colon and breast cancer. These so-called Bovine Meat and Milk Factors (BMMFs) are small DNA molecules that are similar in sequence to both bacterial plasmids and certain viruses.https://www.gesundheitsindustrie-bw.de/en/article/news/new-pathogens-in-beef-and-cows-milk-contributing-to-the-risk-of-cancer
Press release - 19/05/2008 Viruses caught red-handed Prof. Thilo Stehle biochemist at the University of Tübingen wants to capture and accurately study the moment at which a virus binds to a cell. He is hoping that further insights into this process might some time enable the development of drugs.https://www.gesundheitsindustrie-bw.de/en/article/press-release/viruses-caught-red-handed
Press release - 27/09/2018 Three new Clusters of Excellence for Tübingen University takes next hurdle in the German government’s Excellence Strategy funding program. The University of Tübingen is to have three new Clusters of Excellence.As part of the German government’s Excellence Strategy funding forhigher education research, Tübingen will host new outstanding research networks starting in January 2019. Representatives of Germany’s higher education policymakers announced the decision in Bonn on Thursday.https://www.gesundheitsindustrie-bw.de/en/article/press-release/three-new-clusters-of-excellence-for-tuebingen
Expert interview on NTDs – part 1 - 11/04/2019 Neglected tropical diseases – Carsten Köhler: impulses from Baden-Württemberg More than one billion people worldwide suffer from neglected tropical diseases (NTDs). NTDs are mostly poverty-related infectious diseases that prevail in tropical countries due to lack of research and measures to detect, prevent and control them. Dr. Dr. Carsten Köhler reports on the political, economic and scientific contributions Germany and Baden-Württemberg can make to successfully change this situation.https://www.gesundheitsindustrie-bw.de/en/article/news/vernachlaessigte-tropenkrankheiten-carsten-koehler-impulse-aus-baden-wuerttemberg
Press release - 13/05/2020 Corona antibody tests from Reutlingen The NMI Reutlingen is currently tackling a major problem associated with antibody tests for the detection of COVID-19: false positive test results.https://www.gesundheitsindustrie-bw.de/en/article/press-release/corona-antikoerpertests-aus-reutlingen
Overview Basic research The latest articles, press releases and dossiers on basic research in Baden-Württemberghttps://www.gesundheitsindustrie-bw.de/en/article/research
Article - 20/02/2008 Threadworms throughout time Threadworms are versatile research objects and are excellent models for investigating fundamental evolutionary principles. Researchers at the Max Planck Institute for Developmental Biology use the Caenorhabditis and Pristionchus threadworm genera to study the molecular mechanisms of biodiversity.https://www.gesundheitsindustrie-bw.de/en/article/news/threadworms-throughout-time
Article - 23/07/2012 The identification of stress molecules in living fish Fireflies use light to attract mates and hunt prey the zebrafish in Dr. Thomas Dickmeis laboratory mainly glow in situations of stress. The biologist from the Karlsruhe Institute of Technology KIT and two of his doctoral students have created a zebrafish line that can be used as a high-throughput test system for glucocorticoid hormones. Pharmaceutical companies might in future be able to use living vertebrate models i.e. zebrafish to test new…https://www.gesundheitsindustrie-bw.de/en/article/news/the-identification-of-stress-molecules-in-living-fish
Review article (new edition) - 08/07/2020 Immunology – at the forefront of medical progress Immunology is constantly changing with the emergence of new technologies and areas of application, and has branched out in many directions. Immunological approaches are central to everything – be it the development of innovative active substances and vaccinations against cancer, the search for new therapies against neurodegenerative diseases or autoimmune diseases, or combatting well-known infectious diseases or new virus epidemics.https://www.gesundheitsindustrie-bw.de/en/article/dossier/immunology-forefront-medical-progress
Article - 16/11/2008 Looking for a formula to determine biological age The Europe-wide MARK-AGE project involving scientists from 14 countries commenced on the 1st April 2008. Scientists have joined forces to investigate the factors involved in ageing. They are using standardised questionnaires and analysing data acquired from physical and biochemical examinations of the blood and urine from 3700 volunteers. The team of experts includes the medical expert Professor Alexander Bürkle and the mathematician Prof.…https://www.gesundheitsindustrie-bw.de/en/article/news/looking-for-a-formula-to-determine-biological-age
Vaccine development - 02/06/2020 CureVac as a pioneer of mRNA technology – what is behind the novel COVID-19 vaccine? All eyes are on vaccines against the coronavirus. The Tübingen-based company CureVac is doing pioneering work in this field, and intends to initiate clinical testing of its lead vaccine candidate in June. At the same time, Curevac is manufacturing the material for this vaccine candidate. But that’s not all: the novel mRNA technology also has the potential to revolutionise the treatment of cancer and metabolic diseases. What makes the method so…https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-als-pionier-der-mrna-technologie-was-steckt-hinter-dem-neuartigen-covid-19-impfstoff
Article - 18/12/2012 Gene therapy medicinal products: the first gene therapy product has been approved – where does the future lie? Is gene therapy close to broad clinical application? Following negative headlines at the end of the 1990s gene therapy had almost disappeared from the public radar to become an issue almost exclusively dealt with by research laboratories. Gene therapy has now reappeared in the public domain since the European Medicines Agency EMA gave the Dutch biotech company uniQure the go-ahead for the application of somatic gene therapy for the treatment of a…https://www.gesundheitsindustrie-bw.de/en/article/news/gene-therapy-medicinal-products-the-first-gene-therapy-product-has-been-approved-where-does-the-futu